Abstract
Taxanes (paclitaxel and docetaxel) are currently used to treat ovarian, breast, lung, and head and neck cancers. Despite its clinical success taxane-based treatment could be significantly improved by identifying those patients whose tumors are more likely to present a clinical response. In this mini-review we discuss the accumulating evidence indicating that the breast and ovarian cancer susceptibility gene product BRCA1 mediates cellular response to taxanes. We review data from in vitro, animal, and clinical studies, and discuss them in context of response to therapy. We argue that levels of BRCA1 in tumors may provide a predictive marker for the response to treatment with taxanes. In addition, the study of the role of BRCA1 in the mechanism of action of taxanes might reveal alternative approaches to avoid resistance.
Keywords: Taxol, taxane, BRCA1, cancer, biomarker, microtubule, tubulin, chemotherapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?
Volume: 9 Issue: 5
Author(s): J. Thomas DeLigio, Aneliya Velkova, Diego A.R. Zorio and Alvaro N.A. Monteiro
Affiliation:
Keywords: Taxol, taxane, BRCA1, cancer, biomarker, microtubule, tubulin, chemotherapy
Abstract: Taxanes (paclitaxel and docetaxel) are currently used to treat ovarian, breast, lung, and head and neck cancers. Despite its clinical success taxane-based treatment could be significantly improved by identifying those patients whose tumors are more likely to present a clinical response. In this mini-review we discuss the accumulating evidence indicating that the breast and ovarian cancer susceptibility gene product BRCA1 mediates cellular response to taxanes. We review data from in vitro, animal, and clinical studies, and discuss them in context of response to therapy. We argue that levels of BRCA1 in tumors may provide a predictive marker for the response to treatment with taxanes. In addition, the study of the role of BRCA1 in the mechanism of action of taxanes might reveal alternative approaches to avoid resistance.
Export Options
About this article
Cite this article as:
DeLigio Thomas J., Velkova Aneliya, Zorio A.R. Diego and Monteiro N.A. Alvaro, Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (5) . https://dx.doi.org/10.2174/187152009788451798
DOI https://dx.doi.org/10.2174/187152009788451798 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Topical Dermatological Drug Delivery: Quo Vadis?
Current Drug Delivery Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice
Current Genomics Radioprotective Gene Therapy
Current Gene Therapy New Targeted Therapies for Anaplastic Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Epithelial Mesenchymal Transition and Cancer Stem Cell-Like Phenotypes Facilitate Chemoresistance in Recurrent Ovarian Cancer
Current Cancer Drug Targets β -Glucans and their Applications in Cancer Therapy: Focus on human studies
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry γ-H2AX as a Therapeutic Target for Improving the Efficacy of Radiation Therapy
Current Cancer Drug Targets The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets Liposomes as Nanovaccine Delivery Systems
Current Topics in Medicinal Chemistry Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Current Cancer Therapy Reviews Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Current Cancer Drug Targets Correlation Between <i>BCL2</i> and <i>Mcl1</i> Single Nucleotide Polymorphisms and Chemotherapy Response in Jordanian Patients with Colorectal Cancer
Current Pharmaceutical Biotechnology Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Finding Appropriate Signal Peptides for Secretory Production of Recombinant Glucarpidase: An <i>In Silico</i> Method
Recent Patents on Biotechnology Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry Cyclooxygenase-2 Biology
Current Pharmaceutical Design The DNA-Binding and Bioactivity of Rare Earth Metal Complexes
Mini-Reviews in Medicinal Chemistry